EQL Pharma's Chief Business Development Officer (CBDO), Carl Lindgren, increases his shareholding in the company. On November 14[th], Carl Lindgren has bought 10,000 shares in the Company at an ave...
Sales and operating profit growth, new products added to the pipeline
EQL Pharma AB (publ) will publish its interim report for the second quarter, 2024/25, on Wednesday, November 6[th], before stock markets opening.
Today, on 19 August 2024, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below.
Sales and operating profit growth, new products added to the pipeline
